Novartis Venture Fund
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.
Business Model:
Revenue: $34.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Novartis Venture Fund Information
Geographic Data
Address: 355 Main St
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
9,316,027Website Global Rank
166Website Monthly Traffic
Twitter Followers
Description
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100&s;000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. Sectors New therapeutics &a; platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography USA/Canada Europe Switzerland Asia/Pacific
Contact Phone:
+16178713536
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2003 | GlycoMimetics | Series A | 4.3M |
| 8/2018 | Artios Pharma | Series B | 0 |
| 7/2009 | Akebia Therapeutics | Series A | 25M |
| 7/2011 | Myopowers Medical Technologies | Series B | 16M |
| 6/2015 | Myopowers Medical Technologies | Series C | 5.1M |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 6/2007 | BioRelix | Series A | 25.8M |
| 1/2018 | Oculis | Series B | 20.5M |
| 2/2012 | Celladon | Venture Round | 43M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 5/2001 | AGY | Series B | 13M |
| 6/2015 | Realeve | Series D | 43.2M |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
| 6/2015 | Kanyos Bio | Venture Round | 16.4M |
| 2/2022 | Splice Bio | Series A | 0 |
| 8/2006 | Kemia | Series C | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 5/2002 | ESBATech | Series A | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 5/2002 | Kalypsys | Series A | 42M |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 2/2006 | EyeSense AG | Series A | 0 |
| 10/2002 | MerLion Pharma | Series A | 0 |
| 1/2010 | Merus | Series B | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 5/2001 | Polyphor | Venture Round | 9.3M |
| 2/2007 | Trellis Bioscience | Series B | 10M |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 5/2017 | Lemonaid Health | Series A | 0 |
| 10/2011 | Realeve | Series C | 32M |
| 2/2008 | Biofisica | Venture Round | 2.4M |
| 8/2021 | GentiBio | Series A | 157M |
| 6/2007 | Tepha | Series B | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 10/2012 | Neurovance | Venture Round | 7M |
| 4/2014 | Neurovance | Series A | 6.3M |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 11/2007 | Ascent Therapeutics | Series A | 19M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 9/2020 | Novellus | Series C | 57M |
| 9/2009 | PharmAbcine | Series A | 6M |
| 2/2016 | Galera Therapeutics | Series B | 0 |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 8/2004 | GlycoMimetics | Series A | 5.1M |
| 6/2010 | NanoPowers | Series A | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 1/2000 | Viron Therapeutics | Series A | - |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 7/2017 | NeuroVia | Series A | 14M |
| 6/2006 | GlycoMimetics | Series B | 0 |
| 8/2014 | Galera Therapeutics | Series A | 4.7M |
| 3/2007 | Phenomix | Series C | 55M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 10/2009 | Nabriva Therapeutics | Venture Round | 0 |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 6/2007 | Aileron Therapeutics | Series B | 7M |
| 6/2009 | Alios BioPharma | Series A | 24M |
| 4/2007 | Protemix | Series A | 14.5M |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 7/2009 | Avila Therapeutics | Series B | 30M |
| 4/2012 | Advanced Animal Diagnostics | Series B | 4M |
| 6/2009 | Opsona | Series B | 4.6M |
| 9/2016 | Inflazome | Series A | 17M |
| 5/2009 | NovImmune | Venture Round | 0 |
| 10/2013 | Opsona | Series C | 0 |
| 4/2013 | Opsona | Series C | 0 |
| 3/2022 | Epsilogen | Series B | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 10/2020 | Rappta Therapeutics | Series A | 10.6M |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 4/2008 | Aileron Therapeutics | Series C | 10.5M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 8/2004 | Evolva | Series A | 14.8M |
| 2/2006 | Catalyst Biosciences | Series B | 30M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 12/2018 | Annexon Biosciences | Series C | 75M |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 11/2022 | DJEL | Venture Round | 139.4M |
| 1/2015 | Binx Health | Series C | 0 |
| 9/2011 | Eledon Pharmaceuticals | Series D | 23M |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 3/2011 | Euthymics Bioscience | Series A | 4M |
| 8/2006 | ESBATech | Series B | 41M |
| 12/2006 | Evolva | Series A | 10.3M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 12/2008 | Diagnoplex | Series A | 8.3M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 10/2009 | Covagen | Seed Round | - |
| 11/2010 | Covagen | Series A | 6.3M |
| 1/2017 | Binx Health | Series D | 0 |
| 10/2004 | Miikana Therapeutics | Series A | 3M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2019 | Adicet Bio | Series B | 0 |
| 3/2005 | Evolva | Series A | 2.6M |
| 7/2009 | Intellikine | Series B | 51M |
| 8/2008 | ESBATech | Series B | 22M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 6/2007 | Cequent Pharmaceuticals | Series A | 9M |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 5/2014 | Anokion | Series A | 37.5M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 11/2020 | Catalym | Series B | 59.3M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 1/2021 | TScan Therapeutics | Series C | 100M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 4/2011 | ProCertus BioPharm | Series A | 1.7M |
| 8/2010 | Anchor Therapeutics | Series B | 10M |
| 4/2008 | FORMA Therapeutics | Series A | 4M |
| 1/2016 | Adicet Bio | Series A | 51M |
| 2/2007 | Omeros | Series E | 0 |
| 3/2015 | Galera Therapeutics | Series A | 4.7M |
| 12/2005 | Santhera Pharmaceuticals | Series B | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 11/2021 | Capstan Therapeutics | Seed Round | 63M |
| 3/2010 | Immune Targeting Systems | Series A | 13.2M |
| 6/2006 | NovImmune | Series B | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 3/2012 | ImaginAb | Series A | 12.5M |
| 10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
| 4/2015 | Merus | Series C | 79.1M |
| 10/2009 | Bicycle Therapeutics | Seed Round | - |
| 10/2014 | Quartet Medicine | Series A | 17M |
| 10/2013 | Merus | Series B | 42.2M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 1/2010 | MicroCHIPS | Venture Round | 16.5M |
| 12/2017 | Aelin Therapeutics | Series A | 31.8M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 8/2014 | YourBio Health | Series B | 16M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 5/2019 | Cala Health | Series C | 0 |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 12/2012 | Galera Therapeutics | Series A | 11M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 11/2009 | Oxagen | Series C | 0 |
| 3/2020 | Akouos | Series B | 105M |
| 8/2018 | Akouos | Series A | 25.1M |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 7/2019 | TScan Therapeutics | Series B | - |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 5/2006 | Foldrx Pharmaceuticals | Series B | 43M |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 5/2015 | Realeve | Series D | 38M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 7/2009 | Symetis | Series B | 0 |
| 4/2014 | Binx Health | Series B | 0 |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 3/2011 | Advanced Animal Diagnostics | Series B | 11M |
| 4/2007 | MicroCHIPS | Venture Round | 13.4M |
| 12/2019 | Arctos Medical | Seed Round | 0 |
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 9/2012 | F2G | Equity | 30M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 5/2009 | Visiogen | Series D | 40M |
| 12/2020 | Exo Therapeutics | Series A | 25M |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 2/2005 | Covalys Biosciences | Series B | 2.6M |
| 9/2019 | Anokion | Series B | 40M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 11/2004 | Symetis | Series A | 9.6M |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 6/2016 | F2G | Series E | 60M |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 8/2020 | GentiBio | Seed Round | 20M |
| 5/2013 | Eledon Pharmaceuticals | Series E | 35.5M |
| 5/2000 | NovImmune | Series A | 14M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 9/2016 | Rox Medical | Series E | 40M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 12/2006 | Aileron Therapeutics | Series A | 7M |
| 5/2014 | ImaginAb | Series B | 21M |
| 1/2019 | Occlufit | Venture Round | - |
| 4/2013 | Advanced Animal Diagnostics | Series B | 6M |
| 7/2010 | Euthymics Bioscience | Series A | 24M |
| 2/2015 | Altimmune | Post-IPO Equity | 16M |
| 10/2015 | Galera Therapeutics | Series B | 37M |
| 6/2010 | Foldrx Pharmaceuticals | Venture Round | 29M |
| 5/2007 | ProCertus BioPharm | Series A | 2.3M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 7/2009 | ProCertus BioPharm | Venture Round | 2.1M |
| 7/2001 | Nereus Pharmaceuticals | Series B | 23.6M |
| 2/2009 | Alios BioPharma | Series A | 8.4M |
| 8/2019 | Renovacor | Series A | 11M |
| 10/2006 | Biofisica | Series A | 5M |
| 6/2009 | Eledon Pharmaceuticals | Series D | 22M |
| 7/2007 | Neovacs | Venture Round | 17.9M |
| 1/2006 | EraGen Biosciences | Series A | 12M |
| 7/2007 | Immune Targeting Systems | Series A | 7.1M |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 5/2020 | mPharma | Series C | 0 |
| 10/2012 | Thesan Pharmaceuticals | Series A | 16M |
| 9/2004 | Nura | Series A | 9.5M |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 4/2011 | Akebia Therapeutics | Series B | 0 |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 2/2019 | Anaveon | Series A | 35M |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 10/2009 | Evolva | Series B | 27.8M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 3/2022 | Epsilogen | Series B | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
